Breast Cancer
Pipeline by Development Stage
Drug Modality Breakdown
Breast Cancer is a ~$4.3B Part D market in peak maturity, dominated by CDK4/6 inhibitors and kinase inhibitors with limited near-term patent risk.
Key Trends
- CDK4/6 inhibitors (Ibrance, Verzenio, Kisqali) account for 83% of tracked spending—a consolidated standard-of-care class
- Emerging estrogen receptor antagonists and HER2-targeted therapies represent narrow niche growth opportunities
- Heavy trial activity (3,318 trials, 1,009 in Phase 2) signals continued pipeline investment, but market consolidation around existing winners
Career Verdict
Strong career choice for oncology specialists seeking established infrastructure, high salaries, and stable employment; less suitable for entrepreneurial roles or high-growth ambitions.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | IBRANCE (palbociclib) | Pfizer | $2.0B | 47% | PEAK | Stable | 10.7yr |
| 2 | VERZENIO (abemaciclib) | Eli Lilly and Company | $757M | 18% | PEAK | Stable | 5.3yr |
| 3 | KISQALI (ribociclib) | Novartis | $371M | 9% | PEAK | Stable | 9.9yr |
| 4 | PIQRAY (alpelisib) | Novartis | $138M | 3% | PEAK | Stable | 6.9yr |
| 5 | ORSERDU (elacestrant) | Stemline Therapeutics | $128M | 3% | PEAK | Growing | 11.7yr |
Drug Class Breakdown
Consolidated standard-of-care; limited differentiation
Mature, overlap with above class
Niche growth, later-line positioning
Mature, subtype-specific
Declining relevance in modern regimens
Career Outlook
StableBreast cancer remains a cornerstone of oncology portfolios with predictable, high-revenue drugs and established care pathways. Market growth is incremental, driven by biomarker-refined patient segmentation, combination therapies, and emerging mechanisms rather than breakthrough single agents. Career advancement is strongest for professionals who combine oncology domain expertise with health economics, payer strategy, or biomarker/companion diagnostics literacy.
Breaking In
Enter via Commercial or Medical Affairs tracks; a strong foundation in oncology fundamentals (HER2/ER status, standard-of-care sequencing, CDK4/6 rationale) and payer/HCP communication will differentiate you in a crowded field.
For Experienced Professionals
If you have 5+ years in breast cancer or oncology, pivot toward health economics, biomarker commercialization, or pipeline/late-stage project leadership to command $300K+ roles; staying in field-based commercial roles alone will plateau faster as the market matures.
In-Demand Skills
Best For
Hiring Landscape
Breast cancer hiring is concentrated in Commercial (1,666 roles, $255K avg) and Medical Affairs (264 roles, $302K avg), reflecting mature market focus on market access, key opinion leader engagement, and payer negotiations. R&D hiring (331 roles, $222K avg) is steady but not accelerating; manufacturing roles (395, $152K) support stable generic/biosimilar competition. Top hiring companies include AstraZeneca (1,373 roles across portfolio, not breast cancer–specific), indicating that breast cancer specialists are absorbed into larger oncology teams.
Top Hiring Companies
By Department
Solid employment stability and above-average compensation for commercial and medical affairs roles; R&D and clinical roles offer intellectual challenge but narrower entry gates.
On Market (26)
Approved therapies currently available
Competitive Landscape
240 companies ranked by most advanced pipeline stage
+210 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 49 trials with date data
Clinical Trials (50)
Total enrollment: 24,813 patients across 50 trials
Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors
Effect of Neoadjuvant Chemotherapy on Cardiac Function of Perioperative Patients With Breast Cancer and New Strategies for Anesthesia
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression
Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)
Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.
A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization
Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer
Liver Safety Under Upfront Arimidex vs Tamoxifen
Wellbutrin XL, Major Depressive Disorder and Breast Cancer
STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot)
A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer
Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer
Pamidronate Administration in Breast Cancer Patients With Bone Metastases
Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy
6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N+ Breast Cancer
Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer
Effectiveness and Safety Study of Filgrastine® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®
Related Jobs in Oncology
Associate Director, Oncology Lifecycle Management - Hematologic Oncology
Synthetic Medicinal Chemistry Intern
Senior Oncology Account Specialist Breast Cancer Little Rock, AR
Senior Manager, Legal Operations & Contracts
Senior Manager, Legal Operations & Contracts
Senion Oncology Account Specialist Breast Cancer New Brunswick/Edison NJ
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.